Skip to content

RNTX RNTX Other Income (Expense)

Other Income (Expense) at other companies

Gilead Sciences logo
Gilead SciencesGILD
$235M+172%
CTO
Citius Oncology, Inc.CTOR
$1.77M+4,003%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$644K-27.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$29K-72.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$8.47M-678%
LQD
Liquidia CorporationLQDA
-$4.72M-60.5%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's other income (expense)?
RNTX (RNTX) reported other income (expense) of -$608K in Q1 2026.
How has RNTX's other income (expense) changed year-over-year?
RNTX's other income (expense) decreased by 663.0% year-over-year, from $108K to -$608K.
What is the long-term trend for RNTX's other income (expense)?
Over 3 years (2021 to 2024), RNTX's other income (expense) has grown at a 15.8% compound annual growth rate (CAGR), from $441K to $685K.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.